News
McGinley involved in an exciting DARPA-funded project
05/21/2019
A Rice University-led team of neuroengineers is embarking on an ambitious four-year project to develop headset technology that can directly link the human brain and machines without the need for surgery.
MoreMcGinley and Arenkiel involved in an exciting DARPA-funded project
05/21/2019
A Rice University-led team of neuroengineers is embarking on an ambitious four-year project to develop headset technology that can directly link the human brain and machines without the need for surgery.
MoreMcGinley receives John S. Dunn Research Collaborative Award
04/22/2019
Dr, Matthew McGinely receives a seed grant to develop new brain technologies.
MoreFDA approves everolimus for tuberous sclerosis-associated seizures, a treatment first discovered at Texas Children’s Hospital
04/20/2018
On April 10, 2018, the Food and Drug Administration (FDA) approved everolimus tablets for oral suspension (brand name: Afinitor Dispersz, Novartis Pharmaceuticals Corporation) as an adjunctive therapy to treat partial-onset refractory seizures in adults and children over 2 years of age with Tuber
More